FDA OKs Synthon, Breckenridge ANDA for pioglitazone

02/13/2013 | Healio

Synthon Pharmaceuticals and Breckenridge Pharmaceutical have received federal approval for their abbreviated new drug application for pioglitazone in doses of 15, 30 and 45 milligrams. The drug is indicated for type 2 diabetes, along with diet and exercise.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA